PURE · PURE Bioscience, Inc.

On April 30, 2026, PURE Bioscience completed a private placement financing, raising $1.0 million from accredited investors. The company issued 18,131,096 shares of common stock at $0.0553 per share. Notably, two board members participated: Tom Y. Lee invested approximately $700,000 directly and through affiliates, and Ivan Chen invested $27,650. The disinterested board members approved the transaction. The net proceeds, after fees and expenses, are expected to be approximately $1.0 million and will be used for general corporate purposes, including research and development, general administrative expenses, and working capital. The shares were issued in reliance on exemptions from registration under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D. This financing provides additional capital to support the company's ongoing operations and development of its SDC antimicrobial technology.